The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review.

@article{Ferguson2015TheCE,
  title={The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review.},
  author={Thomas W. Ferguson and Yang Xu and R. Chulaka Gunasekara and Blake Lerner and Kerry Macdonald and Claudio Rigatto and Navdeep Tangri and Paul Komenda},
  journal={American journal of nephrology},
  year={2015},
  volume={41 2},
  pages={89-97}
}
BACKGROUND Anemia is a common complication associated with kidney failure and is marked by poor health and increased risk of morbidity and mortality. There are ongoing concerns with the use of Erythropoietin Stimulating Agents (ESAs) to treat anemia in patients with kidney failure on dialysis. Questions as to their benefits, harms and overall effect on quality of life are still relevant today. Our objective was to systematically review studies evaluating the cost-effectiveness of ESAs in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Changes in cost-effectiveness over time. The case of Epoetin Alfa for renal replacement therapy patients in the UK.

The European journal of health economics : HEPAC : health economics in prevention and care • 2003
View 4 Excerpts
Highly Influenced

An economic evaluation of erythropoiesis-stimulating agents in CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation • 2010
View 3 Excerpts
Highly Influenced

Cost-effectiveness of primary screening for CKD: a systematic review.

American journal of kidney diseases : the official journal of the National Kidney Foundation • 2014

Similar Papers

Loading similar papers…